Goodwin Procter LLP advised Social Finance on the deal. Social Finance, Inc. (SoFi) announced its business combination with SPAC Social Capital Hedosophia Holdings Corp. V (SCH) (NYSE:...
Social Finance’s Business Combination with Social Capital Hedosophia Holdings Corp. V
Akili Interactive’s $160 Million Equity and Debt Financing
Goodwin Procter LLP advised Akili Interactive on the deal. Akili Interactive announced its $160 million in combined equity and debt financing. Akili is the maker of EndeavorRx™,...
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
COMPASS Pathways’ $144 Million Shares Offering
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
COMPASS Pathways’ $144 Million Shares Offering
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
Valneva SE’s $107.6 Million Global Offering
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Hogan Lovells and Cooley advised Valneva. Gide advised Goldman Sachs, Jefferies,...
Neuroelectrics’ $17.5 Million Series A Financing
Goodwin Procter LLP advised Neuroelectrics on the deal. Neuroelectrics announced its $17.5 million Series A financing led by Morningside Ventures. Neuroelectrics is developing a therapeutic platform that...
CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals
Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals
Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
Cerevel Therapeutics’ $125 Million Non-dilutive Financing Transaction for Tavapadon
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
Better Therapeutics’ $187 Million Merger Agreement with Mountain Crest Acquisition Corp II
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...